As of November 14, 2026, Abvc Biopharma, Inc. is a publicly traded company (Nasdaq: ABVC). The largest holder reporting an active stake on Schedule 13D is Eugene Jiang, the executive officer and a director, at 18.5%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D/A, July 15, 2025).
Is this your company?
About to sign with, pay or invest in Abvc Biopharma, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Abvc Biopharma, Inc. a real, registered company?
- Abvc Biopharma, Inc. files with the SEC under CIK 1173313 (its SEC filings).
- Its shares are listed under the ticker ABVC on Nasdaq (also ECOC) (SEC company record).
- Incorporated in Nevada; business address in Fremont, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ABVC BIOPHARMA, INC. in our court records and SEC 8-K records (as of 2026-11-14).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Eugene Jiang (filed 2025-07-15).
Who are Abvc Biopharma, Inc.'s owners and officers?
Abvc Biopharma, Inc.: incorporated in Nevada; business address in Fremont, California; industry Pharmaceutical Preparations (424B4, 2026-11-13).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer (Form D, 2026-11-10)
- : Executive Officer, Director (Form D, 2026-11-10)
- : Executive Officer, Director (Form D, 2026-11-10)
- : Director (Form D, 2026-11-10)
- : Director (Form D, 2026-11-10)
- : Director (Form D, 2026-11-10)
- : Director (Form D, 2026-11-10)
- : Director (Form D, 2026-11-10)
- : Director (Form D, 2026-11-10)
- : Director (Form D, 2026-11-10)
- : Director (Form D, 2026-11-10)
- : Director (Form D, 2026-11-10)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2025-08-13 | Lind Global Fund Ii LP | 3.2% |
| Schedule 13D/A, 2025-07-15 | Eugene Jiang | 18.5% |
Questions about who owns Abvc Biopharma, Inc.
Who owns Abvc Biopharma, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Abvc Biopharma, Inc.: Eugene Jiang (18.5%, Schedule 13D/A, filed 2025-07-15).
When did Eugene Jiang buy into Abvc Biopharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Eugene Jiang on this page is the Schedule 13D/A, filed 2025-07-15, reporting 18.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Abvc Biopharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Abvc Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Abvc Biopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
How much has Abvc Biopharma, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-11-10 | $3.39M | $3.39M |
| Form D, 2024-05-28 | $750K | $750K |
| Form D, 2023-03-02 | $3.17M | $3.70M |
Latest IPO step: Abvc Biopharma, Inc. filed its final IPO prospectus (424B4, 2026-11-13).
IPO filings: 424B4, 2026-11-13, 424B4, 2026-11-13, 424B4, 2026-11-13, 424B4, 2026-11-13, 424B4, 2026-08-17.
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-08-27).
Keep reading
More on Abvc Biopharma, Inc. and the records around it.
Abvc Biopharma, Inc. elsewhere on the record
- Company profile and every filing Nov 2026
- 5%+ stake filings Aug 2025
Companies that share a holder
- Lind Global Fund II LP also filed stake reports on 3 other companies: TENAX THERAPEUTICS, INC. (May 2026), WEBUY GLOBAL LTD (Aug 2025)
Related pages
Funding and filing history5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/abvc-biopharma-inc